Insys Therapeutics (INSY) Misses Q1 EPS by 1c

Insys Therapeutics (NASDAQ: INSY) reported Q1 EPS of ($0.19), $0.01 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $23.9 million versus the consensus estimate of $25.66 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.

You May Also Be Interested In

• Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance
• Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
• TJX Cos. (TJX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance